Publications by authors named "Thomas Bumm"

Claim this Profile
E
Elevated red blood cell-derived extracellular vesicles under hyperglycemic conditions are associated with CD47 expression and production of intracellular reactive oxygen species.
Suriyan Sukati, Warangkana Chunglok, Tiwaporn Naulkaew, Thomas Bumm, Surasak Jittivisuthikul

Biomed Rep· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
World first hybrid neuroendocrine cell line sharing properties of NET G3 and dedifferentiated NEC.
Dorothee Rogoll, Laura-Sophie Landwehr, Jochen Schreiner, Philipp Hartrampf, Lea Frey, Thomas Bumm

Eur J Endocrinol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variant signaling topology at the cancer cell-T-cell interface induced by a two-component T-cell engager.
Dina Kouhestani, Maria Geis, Saed Alsouri, Thomas G P Bumm, Hermann Einsele

Cell Mol Immunol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments.
Maria Geis, Boris Nowotny, Marc-Dominic Bohn, Dina Kouhestani, Hermann Einsele, Thomas Bumm

Commun Biol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On-target restoration of a split T cell-engaging antibody for precision immunotherapy.
Agnes Banaszek, Thomas G P Bumm, Boris Nowotny, Maria Geis, Kim Jacob

Nat Commun· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking.
Friederike Braig, Anna Brandt, Mariele Goebeler, Hans-Peter Tony, Anna-Katharina Kurze, Thomas Bumm

Blood· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma.
Tanja Heimberger, Mindaugas Andrulis, Simone Riedel, Thorsten Stühmer, Heike Schraud, Thomas Bumm

Br J Haematol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical activity of the novel orally bioavailable HSP90 inhibitor NVP-HSP990 against multiple myeloma cells.
Thorsten Stühmer, Kamol Iskandarov, Zhenhai Gao, Thomas Bumm, Evelyn Grella

Anticancer Res· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.
Angela G Fleischman, Karl J Aichberger, Samuel B Luty, Thomas G Bumm, Curtis L Petersen

Blood· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
Daniel W Sherbenou, Oliver Hantschel, Ines Kaupe, Stephanie Willis, Thomas Bumm

Blood· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clonal chromosomal abnormalities in CD34+/CD38- hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors.
Thomas Bumm, Jutta Deininger, Amy Hanlon Newell, Helen Lawce, Susan Olson

Leukemia· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.
Jeffrey W Tyner, Thomas G Bumm, Jutta Deininger, Lisa Wood, Karl J Aichberger

Blood· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease.
Anupriya Agarwal, Thomas G P Bumm, Amie S Corbin, Thomas O'Hare, Marc Loriaux

Blood· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of murine JAK2V617F-positive myeloproliferative disease.
Thomas G P Bumm, Collin Elsea, Amie S Corbin, Marc Loriaux, Daniel Sherbenou

Cancer Res· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.
Ian J Griswold, Mary MacPartlin, Thomas Bumm, Valerie L Goss, Thomas O'Hare

Mol Cell Biol· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy.
Thoralf Lange, Thomas Bumm, Sandra Otto, Haifa-Kathrin Al-Ali, Ines Kovacs

Haematologica· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.
Thomas Bumm, Christel Müller, Haifa-Kathrin Al-Ali, Knut Krohn, Patricia Shepherd

Blood· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis